Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03508830 · ClinicalTrials.gov registry record · Phase 3
Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial
A Phase 3 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 3
- Development phase
- 91
- Enrollment target
NCT03508830 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 91 participants.
The verdict
NCT03508830, a Phase 3 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 91 participants
- Enrollment target
Study Summary
The Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial is a single center, double-blind, randomized, active-comparator controlled clinical trial to assess the analgesic efficacy of intercostal nerve block by Liposomal Bupivacaine versus Standard Bupivacaine in subjects undergoing lung resection by robotic or video-assisted thoracoscopic surgery.
Interventions
- DRUG Liposomal bupivacaine
- DRUG Bupivacaine Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2018-12-30 |
| Est. Completion | 2021-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03508830
The ClinicalTrials.gov registry entry for NCT03508830 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal bupivacaine is the first listed.
NCT03508830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03508830 about?
NCT03508830 is a clinical study titled "Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial". The Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial is a single center, double-blind, randomized, active-comparator controlled clinical trial to assess the analgesic efficacy of intercostal nerve block by Liposomal Bupivacaine versus Standard Bupivacaine in subjects undergoing lung...
What is the current status of trial NCT03508830?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 91 participants. The study started on 2018-12-30. Estimated completion is 2021-01-30.
What interventions are being tested in trial NCT03508830?
The interventions under investigation include: Liposomal bupivacaine (DRUG), Bupivacaine Injection (DRUG).
Who is sponsoring clinical trial NCT03508830?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.